Brief: Deciphera Announces Approval Of Qinlock In The United Kingdom For The Treatment Of Fourth-Line Gastrointestinal Stromal Tumor
21/12/2021 13:46
Dec 21 (Reuters) - Deciphera Pharmaceuticals Inc DCPH.O :
* DECIPHERA ANNOUNCES APPROVAL OF QINLOCK® IN THE UNITED
KINGDOM
FOR THE TREATMENT OF FOURTH-LINE GASTROINTESTINAL STROMAL TUMOR
Source text for Eikon: ID:nBwc0Zr4Ja
Further company coverage: DCPH.O
Recent news on Deciphera Pharmaceuticals
See all newsBrief: Deciphera Pharmaceuticals Announces Oral Presentation Of Results From Phase 3 Study of Vimseltinib In Patients With Tenosynovial Giant Cell Tumor
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
Deals of the day-Mergers and acquisitions